Cansino's COVID-19 Vaccine Candidate Approved For Military Use In China

China's military has received the greenlight to use a COVID-19 vaccine candidate developed by its research unit and CanSino Biologics after clinical trials proved it was safe and somewhat efficient, the company said on Monday.

The Ad5-nCoV is one of the eight vaccine candidates being developed by Chinese companies and researchers approved to be moved into human trials for the respiratory disease caused by the new coronavirus. The shot also won approval for human testing in Canada.

China's Central Military Commission approved the use of the vaccine by the military on June 25 for a period of one year, CanSino said in a filing. The vaccine candidate was developed jointly by CanSino and the Beijing Institute of Biotechnology in the Academy of Military Medical Sciences.

"The Ad5-nCoV is currently limited to military use only and its use cannot be expanded to a broader vaccination range without the approval of the Logistics Support Department," CanSino said, referring to the Central Military Commission department where the military use of the vaccine was approved.

The Phase 1 and Phase 2 clinical trials showed the vaccine candidate has potential to prevent diseases caused by the coronavirus, which has killed half a million people globally, but its commercial success cannot be guaranteed, the company said.

No vaccine has yet been approved for commercial use against the illness caused by the new coronavirus, but over a dozen vaccines from more than 100 candidates globally are being tested in humans.

(Reporting by Roxanne Liu and Ryan Woo; Editing by Miyoung Kim and Ana Nicolaci da Costa)